Valneva SE reported further positive phase III data in adolescents for its single-shot chikungunya virus (Chikv) vaccine Ixchiq
Valneva SE reported further positive Phase III data in adolescents for its single-shot chikungunya virus (Chikv) vaccine, Ixchiq, which showed a sustained 98.3% sero-response rate one-year after single… read more.